| ZYC300 |
| | For the treatment of various forms of cancer. |
| Zalutumumab |
Epidermal growth factor receptor | | |
| XTL-001 |
| | Investigated for use/treatment in hepatitis (viral, B). |
| XOMA 052 |
Interleukin-1 beta | | Investigated for use/treatment in diabetes mellitus type 2. |
| VPM4001 |
| | Investigated for use/treatment in prostate cancer. |
| VIR201 |
Interferon gamma | | Investigated for use/treatment in HIV infection. |
| Velaglucerase alfa |
Glucosylceramidase | A16AB10 | Velaglucerase alfa is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy for pediatric and adult patients with type 1 Gaucher disease. |
| Vedolizumab |
Integrin alpha-4;Integrin beta-7 | L04AA33 | Vedolizumab is indicated for adult patients with moderately to severely active UC or CD who have had an inadequate response with, lost response to, or were intolerant to a tumor necrosis factor (TNF) blocker or immunomodulator; or had an inadequate respon |
| VB2-011 |
| | Investigated for use/treatment in cancer/tumors (unspecified). |
| Vasopressin |
Vasopressin V2 receptor;Vasopressin V1a receptor;Vasopressin V1b receptor | H01BA06 | For the treatment of enuresis, polyuria, diabetes insipidus, polydipsia and oesophageal varices with bleeding |
| Ustekinumab |
Interleukin-12 subunit beta;Interleukin-23 (Protein Group) | L04AC05 | Ustekinumab is indicated for management of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy; or is used alone or in conjunction with methotrexate for the management of active psoriatic arthritis in adul |
| Urokinase |
Plasminogen;Urokinase plasminogen activator surface receptor;Urokinase-type plasminogen activator;Tissue-type plasminogen activator;Plasminogen activator inhibitor 1;Plasminogen activator inhibitor 2;Plasma serine protease inhibitor;Low-density lipoprotein receptor-related protein 2;Suppressor of tumorigenicity 14 protein;Nidogen-1 | B01AD04 | Urokinase can be used for the treatment of pulminary embolism, coronary artery thrombosis, IV catheter clearance, and venous and arterial blood clots. |
| Urofollitropin |
Follicle-stimulating hormone receptor | G03GA04 | For treatment of female infertility |
| Ty800 |
| | For the production of immunity to Salmonella typhi, the cause of typhoid fever. |
| Turoctocog alfa |
| | |
| Tuberculin Purified Protein Derivative |
| | Indicated as an aid in the detection of infection with Mycobacterium tuberculosis. |
| TRX1 |
| | Investigated for use/treatment in autoimmune diseases. |
| Trastuzumab emtansine |
Receptor tyrosine-protein kinase erbB-2 | L01XC14 | Used in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic disease or had their cancer recur within 6 months of adjuvant treatment. |
| Trastuzumab |
Receptor tyrosine-protein kinase erbB-2;Epidermal growth factor receptor;Complement C1r subcomponent;Complement C1q subcomponent subunit A;Complement C1q subcomponent subunit B;Complement C1q subcomponent subunit C;Complement C1s subcomponent;High affinity immunoglobulin gamma Fc receptor I;Low affinity immunoglobulin gamma Fc region receptor II-a;Low affinity immunoglobulin gamma Fc region receptor II-b;Low affinity immunoglobulin gamma Fc region receptor II-c;Low affinity immunoglobulin gamma Fc region receptor III-B;Low affinity immunoglobulin gamma Fc region receptor III-A | L01XC03 | For treatment of early stage HER2-positive breast cancer, or metastatic breast cancer that substantially overexpress HER2. |
| Tositumomab |
B-lymphocyte antigen CD20;Low affinity immunoglobulin gamma Fc region receptor III-B;Complement C1r subcomponent;Complement C1q subcomponent subunit A;Complement C1q subcomponent subunit B;Complement C1q subcomponent subunit C;Low affinity immunoglobulin gamma Fc region receptor III-A;High affinity immunoglobulin gamma Fc receptor I;Low affinity immunoglobulin gamma Fc region receptor II-a;Low affinity immunoglobulin gamma Fc region receptor II-b;Low affinity immunoglobulin gamma Fc region receptor II-c | | For treatment of non-Hodgkin's lymphoma (CD20 positive, follicular) |
